CapiTainer

The company’s business model is centered on the sale of its patented, disposable self-sampling devices, which generates recurring revenue. These devices are sold to laboratories, healthcare providers, and research institutions. Capitainer utilizes a value-based and competitive pricing strategy, often customizing prices for B2B clients. The firm targets the growing direct-to-consumer and decentralized clinical trial markets, aiming to reduce healthcare costs and logistical complexities associated with traditional sample collection.

CapiTainer's core technology, quantitative Dried Blood Spot (qDBS), uses microfluidics to ensure a precise, fixed volume of a biological sample is collected, eliminating the user- and hematocrit-related variability common in other methods. The product portfolio includes various CE-marked and FDA-registered cards like the Capitainer®B10 and Capitainer®B50 for different volumes of whole blood, and the Capitainer®SEP10 for plasma separation. These devices allow patients to collect samples at home with a simple finger prick, which can then be sent to a lab via regular mail without needing refrigeration. This technology supports a wide range of analyses, including therapeutic drug monitoring, public health screenings for infectious diseases like COVID-19, and testing for biomarkers in proteomics and oncology. In November 2024, Capitainer expanded its operations by opening a laboratory in Rhode Island, USA, to support its commercialization efforts in the American market.